Apalutamide for the treatment of patients with castration-resistant prostate cancer.

• Autores: Hauke R. Heekeren
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 54, Nº. 10, 2018, págs. 585-590
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Patients with recurrent, nonmetastatic prostate cancer after curative intent therapy can experience a heterogeneous clinical course ranging from indolent disease that can be observed for years to a rapidly progressive disease that is metastatic in a relatively short time. Patients with short prostate-specific antigen (PSA) doubling times are at risk for early development of metastatic disease and are frequently placed on androgen deprivation therapy. Although castration-resistant disease inevitably occurs in these patients, most therapies for castration-resistant disease have shown benefit in the metastatic setting. Apalutamide is a nonsteroidal antiandrogen agent that binds directly to the ligand-binding domain of the androgen receptor, preventing androgen receptor translocation, DNA binding and androgen receptor-mediated transcription. Apalutamide showed improved metastasis-free survival and prolonged time to symptomatic progression in men with nonmetastatic castration-resistant prostate cancer with a short PSA doubling time.